ADR 002
Alternative Names: ADR-002; ADR-002KLatest Information Update: 06 Oct 2025
At a glance
- Originator Osaka University Hospital; Rohto Pharmaceutical
- Class Cardiovascular therapies; Gene therapies; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Cardiomyopathies
Most Recent Events
- 25 Sep 2025 ADR 002 is still in phase I trials for cardiomyopathies in Japan.
- 25 Sep 2025 Rohto Pharmaceuticals plans a phase II trial for Chronic heart failure in an unknown location in September 2025 (NCT07192211) (jRCT2053250022)
- 16 Nov 2024 Efficacy and adverse events data from a phase I trial Cardiomyophathies presented at the American Heart Association Scientific Sessions 2024 (AHA-2024)